257 related articles for article (PubMed ID: 31794465)
1. Facioscapulohumeral Muscular Dystrophies.
Wagner KR
Continuum (Minneap Minn); 2019 Dec; 25(6):1662-1681. PubMed ID: 31794465
[TBL] [Abstract][Full Text] [Related]
2. Facioscapulohumeral Muscular Dystrophy.
Statland JM; Tawil R
Continuum (Minneap Minn); 2016 Dec; 22(6, Muscle and Neuromuscular Junction Disorders):1916-1931. PubMed ID: 27922500
[TBL] [Abstract][Full Text] [Related]
3. Facioscapulohumeral Muscular Dystrophy.
Mul K
Continuum (Minneap Minn); 2022 Dec; 28(6):1735-1751. PubMed ID: 36537978
[TBL] [Abstract][Full Text] [Related]
4. Facioscapulohumeral Muscular Dystrophy: Update on Pathogenesis and Future Treatments.
Hamel J; Tawil R
Neurotherapeutics; 2018 Oct; 15(4):863-871. PubMed ID: 30361930
[TBL] [Abstract][Full Text] [Related]
5. Facioscapulohumeral muscular dystrophy.
Tawil R
Handb Clin Neurol; 2018; 148():541-548. PubMed ID: 29478599
[TBL] [Abstract][Full Text] [Related]
6. Facioscapulohumeral muscular dystrophy.
Statland J; Tawil R
Neurol Clin; 2014 Aug; 32(3):721-8, ix. PubMed ID: 25037087
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic approach for FSHD revisited: SMCHD1 mutations cause FSHD2 and act as modifiers of disease severity in FSHD1.
Larsen M; Rost S; El Hajj N; Ferbert A; Deschauer M; Walter MC; Schoser B; Tacik P; Kress W; Müller CR
Eur J Hum Genet; 2015 Jun; 23(6):808-16. PubMed ID: 25370034
[TBL] [Abstract][Full Text] [Related]
8. [Facioscapulohumeral muscular dystrophy type 2].
Sacconi S; Desnuelle C
Rev Neurol (Paris); 2013; 169(8-9):564-72. PubMed ID: 23969240
[TBL] [Abstract][Full Text] [Related]
9. A complex interplay of genetic and epigenetic events leads to abnormal expression of the DUX4 gene in facioscapulohumeral muscular dystrophy.
Gatica LV; Rosa AL
Neuromuscul Disord; 2016 Dec; 26(12):844-852. PubMed ID: 27816329
[TBL] [Abstract][Full Text] [Related]
10. Facioscapulohumeral Muscular Dystrophy.
DeSimone AM; Pakula A; Lek A; Emerson CP
Compr Physiol; 2017 Sep; 7(4):1229-1279. PubMed ID: 28915324
[TBL] [Abstract][Full Text] [Related]
11. Facioscapulohumeral muscular dystrophy type 2: an update on the clinical, genetic, and molecular findings.
Jia FF; Drew AP; Nicholson GA; Corbett A; Kumar KR
Neuromuscul Disord; 2021 Nov; 31(11):1101-1112. PubMed ID: 34711481
[TBL] [Abstract][Full Text] [Related]
12. Identification of variants in the 4q35 gene FAT1 in patients with a facioscapulohumeral dystrophy-like phenotype.
Puppo F; Dionnet E; Gaillard MC; Gaildrat P; Castro C; Vovan C; Bertaux K; Bernard R; Attarian S; Goto K; Nishino I; Hayashi Y; Magdinier F; Krahn M; Helmbacher F; Bartoli M; Lévy N
Hum Mutat; 2015 Apr; 36(4):443-53. PubMed ID: 25615407
[TBL] [Abstract][Full Text] [Related]
13. Exome sequencing identifies a novel SMCHD1 mutation in facioscapulohumeral muscular dystrophy 2.
Mitsuhashi S; Boyden SE; Estrella EA; Jones TI; Rahimov F; Yu TW; Darras BT; Amato AA; Folkerth RD; Jones PL; Kunkel LM; Kang PB
Neuromuscul Disord; 2013 Dec; 23(12):975-80. PubMed ID: 24128691
[TBL] [Abstract][Full Text] [Related]
14. Identification of two novel SMCHD1 sequence variants in families with FSHD-like muscular dystrophy.
Winston J; Duerden L; Mort M; Frayling IM; Rogers MT; Upadhyaya M
Eur J Hum Genet; 2015 Jan; 23(1):67-71. PubMed ID: 24755953
[TBL] [Abstract][Full Text] [Related]
15. Integrating clinical and genetic observations in facioscapulohumeral muscular dystrophy.
Mul K; van den Boogaard ML; van der Maarel SM; van Engelen BG
Curr Opin Neurol; 2016 Oct; 29(5):606-13. PubMed ID: 27389814
[TBL] [Abstract][Full Text] [Related]
16. Identification of Serum Interleukin 6 Levels as a Disease Severity Biomarker in Facioscapulohumeral Muscular Dystrophy.
Gros M; Nunes AM; Daoudlarian D; Pini J; Martinuzzi E; Barbosa S; Ramirez M; Puma A; Villa L; Cavalli M; Grecu N; Garcia J; Siciliano G; Solé G; Juntas-Morales R; Jones PL; Jones T; Glaichenhaus N; Sacconi S
J Neuromuscul Dis; 2022; 9(1):83-93. PubMed ID: 34459413
[TBL] [Abstract][Full Text] [Related]
17. Intronic
Goossens R; van den Boogaard ML; Lemmers RJLF; Balog J; van der Vliet PJ; Willemsen IM; Schouten J; Maggio I; van der Stoep N; Hoeben RC; Tapscott SJ; Geijsen N; Gonçalves MAFV; Sacconi S; Tawil R; van der Maarel SM
J Med Genet; 2019 Dec; 56(12):828-837. PubMed ID: 31676591
[TBL] [Abstract][Full Text] [Related]
18. Monosomy 18p is a risk factor for facioscapulohumeral dystrophy.
Balog J; Goossens R; Lemmers RJLF; Straasheijm KR; van der Vliet PJ; Heuvel AVD; Cambieri C; Capet N; Feasson L; Manel V; Contet J; Kriek M; Donlin-Smith CM; Ruivenkamp CAL; Heard P; Tapscott SJ; Cody JD; Tawil R; Sacconi S; van der Maarel SM
J Med Genet; 2018 Jul; 55(7):469-478. PubMed ID: 29563141
[TBL] [Abstract][Full Text] [Related]
19. Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study.
LoRusso S; Johnson NE; McDermott MP; Eichinger K; Butterfield RJ; Carraro E; Higgs K; Lewis L; Mul K; Sacconi S; Sansone VA; Shieh P; van Engelen B; Wagner K; Wang L; Statland JM; Tawil R;
BMC Neurol; 2019 Sep; 19(1):224. PubMed ID: 31506080
[TBL] [Abstract][Full Text] [Related]
20. Identifying diagnostic DNA methylation profiles for facioscapulohumeral muscular dystrophy in blood and saliva using bisulfite sequencing.
Jones TI; Yan C; Sapp PC; McKenna-Yasek D; Kang PB; Quinn C; Salameh JS; King OD; Jones PL
Clin Epigenetics; 2014; 6(1):23. PubMed ID: 25400706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
